GlassScriptPhysician profile
Susan P Compton
NPI 1942398771
$8,532.08
in general payments reported to CMS, 2019-2025
33 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $297 · 2021: $408 · 2022: $1,039 · 2023: $670 · 2024: $4,582 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Travel and Lodging: $1,018 · Education: $48.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.57 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Travel and Lodging | $1,017.79 |
| Education | $48.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $4,167.56 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $615.79 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $420.84 | 2022-2025 | |
| Amgen INC. | $370.45 | 2019-2024 | Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $316.50 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $316.00 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $304.21 | 2022-2023 | Lupkynis |
| Vifor Pharma, INC. | $285.68 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $270.32 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $179.94 | 2019-2024 | Jynarque |
| Baxter Healthcare | $159.93 | 2019-2023 | Renal - Pd |
| Glaxosmithkline, LLC. | $135.71 | 2021-2023 | Benlysta |
| Nxstage Medical, INC. | $115.46 | 2021 | |
| Scpharmaceuticals INC. | $80.98 | 2025 | |
| Horizon Therapeutics Plc | $79.27 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $77.95 | 2025 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.95 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $73.64 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $69.11 | 2022-2023 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $60.73 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $52.08 | 2019 | |
| Lilly USA, LLC | $40.81 | 2024 | Jardiance |
| Amicus Therapeutics, INC. | $35.46 | 2022 | |
| Novo Nordisk INC | $28.86 | 2025 | Rybelsus, Ozempic |
| Apellis Pharmaceuticals, INC. | $28.16 | 2025 | Empaveli |
| Merck Sharp & Dohme LLC | $24.86 | 2025 | Verquvo |
| Daiichi Sankyo INC. | $24.08 | 2019 | |
| Allergan, INC. | $23.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.92 | 2019-2020 | |
| Shire North American Group INC | $22.71 | 2019 | |
| Chiesi USA, INC. | $20.13 | 2025 | Elfabrio |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.